Welcome to our dedicated page for LIXTE BIOTECHNOLOGY HOLDINGS SEC filings (Ticker: LIXTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIXTE BIOTECHNOLOGY HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIXTE BIOTECHNOLOGY HOLDINGS's regulatory disclosures and financial reporting.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) filed an 8-K reporting that it entered into a Securities Purchase Agreement on 3 July 2025 for a registered direct offering that closed on 8 July 2025.
Transaction terms: the company sold 210,675 common shares and pre-funded warrants covering 763,351 shares at an offering price of $1.54 per share (or $1.53999 per warrant), generating gross proceeds of approximately $1.5 million before deductions.
Placement agent: Spartan Capital Securities, LLC acted as exclusive placement agent, earning a cash fee equal to 8 % of gross proceeds and reimbursement of $40,000 in legal fees under a separate Placement Agent Agreement.
Exhibits: the filing includes the Form of Pre-Funded Warrant (4.1), legal opinion from TroyGould PC (5.1), Securities Purchase Agreement (10.1), Placement Agent Agreement (10.2) and the related press release (99.1).
The report emphasizes that the agreements’ representations and warranties are made solely between the contracting parties and may employ materiality standards different from those of public investors.